1262875-28-4

Basic information

• Product Name: methyl 6-(6-methoxy-2-phenyl-1H-indol-3-ylmethyl)pyridine-2-carboxylate
• Synonyms: methyl 6-(6-methoxy-2-phenyl-1H-indol-3-ylmethyl)pyridine-2-carboxylate
• CAS NO: 1262875-28-4
• Molecular Weight: 372.423
• Mol File: 1262875-28-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 6-(6-methoxy-2-phenyl-1H-indol-3-ylmethyl)pyridine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 6-(6-methoxy-2-phenyl-1H-indol-3-ylmethyl)pyridine-2-carboxylate(1262875-28-4)
• EPA Substance Registry System: methyl 6-(6-methoxy-2-phenyl-1H-indol-3-ylmethyl)pyridine-2-carboxylate(1262875-28-4)

Safety Data

• Hazardous Substances Data: 1262875-28-4(Hazardous Substances Data)

Upstream product

• 138343-79-0 (5-methoxy-2-methyl-phenyl)-carbamic acid t-butyl ester 
• 50868-72-9 5-methoxy-o-toluidine 
• 1262879-72-0 methyl 6-[2-(2-tert-butoxycarbonylamino-4-methoxyphenyl)-3-oxo-3-phenylpropyl]pyridine-2-carboxylate 
• 1262879-51-5 tert-butyl [5-methoxy-2-(2-oxo-2-phenylethyl)phenyl]carbamate 

Downstream Products

• 1262875-83-1 6-(6-methoxy-2-phenyl-1H-indol-3-ylmethyl)pyridine-2-carboxylic acid 

Relevant articles and documents

INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

The present invention provides a compound represented by the general formula (I) of the present invention, which has EP1 receptor antagonism: wherein A represents a benzene ring, a pyridine ring, or the like; Y1 represents a C1-6 alkylene group or the like; Y2 represents a single bond or the like; Z represents —C(═O)—NHSO2R6, an acidic 5-membered hetero ring group, or the like; R1 represents a hydrogen atom or the like; R2 represents a phenyl group, a 5-membered aromatic heterocyclic group, or the like; R3 represents a halogen atom, a C1-6 alkoxy group, or the like; R4 represents a hydrogen atom, a halogen atom, or the like; R5 represents a hydrogen atom or the like; and R6 represents a C1-6 alkyl group or the like], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.